5-Substituted-1H-tetrazoles as carboxylic acid isosteres: medicinal chemistry and synthetic methods.

5-Substituted-1H-tetrazoles (RCN4H) are often used as metabolism-resistant isosteric replacements for carboxylic acids (RCO2H) in SAR-driven medicinal chemistry analogue syntheses. This review provides a brief summary of the medicinal chemistry of tetrazolic acids and highlights some examples of tetrazole-containing drug substances in the current literature. A survey of representative literature procedures for the preparation of 5-substituted-1H-tetrazoles, focusing on preparations from aryl and alkyl nitriles, is presented in sections by generalized synthetic methods.

[1]  C. C. Kotoris,et al.  Novel phosphate mimetics for the design of non-peptidyl inhibitors of protein tyrosine phosphatases. , 1998, Bioorganic & medicinal chemistry letters.

[2]  T. Kato,et al.  Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids. , 1993, Journal of medicinal chemistry.

[3]  D. Moderhack.  Ring Transformations in Tetrazole Chemistry , 1999 .

[4]  B. Burchell,et al.  Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation. , 1995, Life sciences.

[5]  B. C. May,et al.  The synthesis and crystal structure of alpha-keto tetrazole-based dipeptide mimics , 2001 .

[6]  Green,et al.  Parallel Synthesis of Alkyl Tetrazole Derivatives Using Solid Support Chemistry. , 2000, Journal of combinatorial chemistry.

[7]  T. Goodson,et al.  LY171883, 1-less than 2-hydroxy-3-propyl-4-less than 4-(1H-tetrazol-5-yl) butoxy greater than phenyl greater than ethanone, an orally active leukotriene D4 antagonist. , 1985, The Journal of pharmacology and experimental therapeutics.

[8]  J. Duncia,et al.  Three synthetic routes to a sterically hindered tetrazole. A new one-step mild conversion of an amide into a tetrazole , 1991 .

[9]  R. M. Herbst,et al.  TETRAZOLE ANALOGUES OF GLUTAMIC ACID. I. REACTION WITH GLUTAMIC DEHYDROGENASE. , 1965, The Journal of biological chemistry.

[10]  G. Rork,et al.  Investigation of N-[(acyloxy) alkyl] ester as a prodrug model for drugs containing the phenyltetrazole moiety. , 1994, Journal of pharmaceutical sciences.

[11]  A. Jackman,et al.  Quinazoline antifolate thymidylate synthase inhibitors: replacement of glutamic acid in the C2-methyl series. , 1995, Journal of medicinal chemistry.

[12]  Michael A. Staszak,et al.  A new method for the preparation of tetrazoles from nitriles using trimethylsilylazide/trimethylaluminum , 1993 .

[13]  A. S. Chawla,et al.  Medicinal chemistry of tetrazoles. , 1980, Progress in medicinal chemistry.

[14]  A. Jackman,et al.  Design and synthesis of potent non-polyglutamatable quinazoline antifolate thymidylate synthase inhibitors. , 1999, Journal of medicinal chemistry.

[15]  J. N. Pereira,et al.  Heterocyclic tetrazoles, a new class of lipolysis inhibitors. , 1967, Journal of medicinal chemistry.

[16]  M. Green,et al.  Glucuronidation of amine substrates by purified and expressed UDP-glucuronosyltransferase proteins. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[17]  R. A. Henry,et al.  Platinum- and palladium-tetrazole complexes , 1970 .

[18]  V. Segarra,et al.  Phosphodiesterase inhibitory properties of losartan. Design and synthesis of new lead compounds. , 1998, Bioorganic & medicinal chemistry letters.

[19]  D. Woodbury,et al.  The fate and excretion of C14-labeled pentylenetetrazol in the rat, with comments on analytical methods for pentylenetetrazol. , 1956, The Journal of pharmacology and experimental therapeutics.

[20]  Y. Satoh,et al.  HOMOLOGATION OF 1-(BENZYLOXYMETHYL)-1H-TETRAZOLE VIA LITHIATION , 1998 .

[21]  Olesen Ph,et al.  The use of bioisosteric groups in lead optimization. , 2001 .

[22]  Rodney L. Johnson,et al.  Synthesis and Chemical Properties of Tetrazole Peptide Analogues , 1987 .

[23]  K Prendergast,et al.  Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy. , 1996, Journal of medicinal chemistry.

[24]  K. Inoguchi,et al.  Rational design, discovery, and synthesis of a novel series of potent growth hormone secretagogues. , 2001, Journal of medicinal chemistry.

[25]  R. DeVita,et al.  BENZOLACTAM GROWTH HORMONE SECRETAGOGUES : CARBOXAMIDES AS REPLACEMENTS FOR THE 2'-TETRAZOLE MOIETY OF L-692,429 , 1994 .

[26]  R. M. Herbst,et al.  Tetrazole Analogs of Amino Acids1 , 1959 .

[27]  G. Cohen,et al.  Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[28]  K. Rossen,et al.  Synthesis of the orally active spiroindoline-based growth hormone secretagogue, MK-677 , 1997 .

[29]  W. Price,et al.  Nonpeptide angiotensin II receptor antagonists: the discovery of a series of N-(biphenylylmethyl)imidazoles as potent, orally active antihypertensives. , 1991, Journal of medicinal chemistry.

[30]  R. Krell,et al.  A novel series of selective leukotriene antagonists: exploration and optimization of the acidic region in 1,6-disubstituted indoles and indazoles. , 1990, Journal of medicinal chemistry.

[31]  E. LaVoie,et al.  Bioisosterism: A Rational Approach in Drug Design. , 1996, Chemical reviews.

[32]  R. Miller,et al.  The metabolism of DuP 753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey, and human liver slices. , 1992, Drug metabolism and disposition: the biological fate of chemicals.

[33]  B. Jursic,et al.  Preparation of tetrazoles from organic nitriles and sodium azide in micellar media , 1998 .

[34]  Robert B. Hermann,et al.  OVID and SUPER: Two overlap programs for drug design , 1991, J. Comput. Aided Mol. Des..

[35]  Peter Buhlmayer,et al.  Patent Update: Angiotensin-II Antagonists: Patent Activity since the Discovery of DuP-753 , 1992 .

[36]  R. N. Butler.  4.17 – Tetrazoles , 1996 .

[37]  Conrad A. Roten,et al.  Novel Syntheses of 2-Butyl-5-chloro-3H-imidazole-4-carbaldehyde: A Key Intermediate for the Synthesis of the Angiotensin II Antagonist Losartan. , 1999, The Journal of organic chemistry.

[38]  R. Graham,et al.  Tetrazole and Carboxylate Groups of Angiotensin Receptor Antagonists Bind to the Same Subsite by Different Mechanisms (*) , 1995, The Journal of Biological Chemistry.

[39]  R. DeVita,et al.  A potent, orally bioavailable benzazepinone growth hormone secretagogue. , 1998, Journal of medicinal chemistry.

[40]  James R. Moore,et al.  Efficient Synthesis of Losartan, A Nonpeptide Angiotensin II Receptor Antagonist , 1994 .

[41]  Derek P. G. Norman,et al.  Nucleophilic Aromatic Substitution Reactions of Novel 5-(2-Methoxyphenyl)tetrazole Derivatives with Organolithium Reagents , 1999 .

[42]  S. Karnik,et al.  The Docking of Arg2 of Angiotensin II with Asp281 of AT1 Receptor Is Essential for Full Agonism (*) , 1995, The Journal of Biological Chemistry.

[43]  Johan Svensson,et al.  Growth hormone secretagogues , 2000 .

[44]  J. Magdalou,et al.  In vitro N-glucuronidation of SB 47436 (BMS 186295), a new AT1 nonpeptide angiotensin II receptor antagonist, by rat, monkey and human hepatic microsomal fractions. , 1994, The Journal of pharmacology and experimental therapeutics.

[45]  A. Albert.  3H-1,2,3,4,6-penta-azaindenes (“8-azapurines.”) Part I. Covalent hydration, syntheses, and reductions , 1966 .

[46]  A. Koren,et al.  Alkylation and Related Electrophilic Reactions at Endocyclic Nitrogen Atoms in the Chemistry of Tetrazoles , 2000 .

[47]  P. Timmermans,et al.  The discovery of DuP 753, a potent, orally active nonpeptide angiotensin II receptor antagonist , 1992, Medicinal research reviews.

[48]  J. Kraus,et al.  Isosterism and molecular modification in drug design: tetrazole analogue of GABA: effects on enzymes of the gamma-aminobutyrate system. , 1983, Pharmacological research communications.

[49]  E. Imamiya,et al.  Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazolecarboxylic acids. , 1993, Journal of medicinal chemistry.

[50]  R. A. Henry,et al.  An Improved Synthesis of 5-Substituted Tetrazoles , 1958 .

[51]  C. Toniolo,et al.  Synthesis and X-ray diffraction analysis of the tetrazole peptide analogue Pro-LeuΨ[CN4]Gly-NH2 , 1988 .

[52]  K. Cassidy,et al.  Characterization of 2-[[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]methyl]quinoline N-glucuronidation by in vitro and in vivo approaches. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[53]  E. Convey,et al.  The synergistic effects of His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 on growth hormone (GH)-releasing factor-stimulated GH release and intracellular adenosine 3',5'-monophosphate accumulation in rat primary pituitary cell culture. , 1989, Endocrinology.

[54]  R. DeVita,et al.  Benzolactam growth hormone secretagogues: replacements for the 2′-tetrazole moiety of L-692,429 , 1994 .

[55]  S. Chong,et al.  Prodrugs of BMS-183920: metabolism and permeability considerations. , 1996, Journal of pharmaceutical sciences.

[56]  R. M. Herbst,et al.  Apparent Acidic Dissociation of Some 5-Aryltetrazoles1 , 1957 .

[57]  R. Miller,et al.  N-glucuronidation reactions. I. Tetrazole N-glucuronidation of selected angiotensin II receptor antagonists in hepatic microsomes from rats, dogs, monkeys, and humans. , 1993, Drug metabolism and disposition: the biological fate of chemicals.

[58]  S. K. Figdor,et al.  Metabolism of 5-(3-pyridyl)tetrazole. , 1967, Journal of medicinal chemistry.

[59]  C. Thornber,et al.  Isosterism and molecular modification in drug design , 1979 .

[60]  T Mavromoustakos,et al.  An effort to understand the molecular basis of hypertension through the study of conformational analysis of losartan and sarmesin using a combination of nuclear magnetic resonance spectroscopy and theoretical calculations. , 1999, Journal of medicinal chemistry.

[61]  G. Siest,et al.  N-glucuronidation reactions. III. Regioselectivity of N-glucuronidation of methylbiphenyl tetrazole, methylbiphenyl triazole, and methylbiphenyl imidazole using human and rat recombinant UDP-glucuronosyltransferases stably expressed in V79 cells. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[62]  Z. Grzonka,et al.  Tetrazole analogues of amino acids and peptides IV , 1971 .

[63]  E. Lieber,et al.  Synthesis and Properties of 5-(Substituted) Mercaptotetrazoles1 , 1961 .

[64]  J. V. Braun,et al.  Synthese von Tetrazol‐Verbindungen aus Säurenitrilen , 1932 .

[65]  L. V. D. van der Ploeg,et al.  Development of a high specific activity sulfur-35-labeled sulfonamide radioligand that allowed the identification of a new growth hormone secretagogue receptor. , 1996, Journal of medicinal chemistry.

[66]  D. K. Herron,et al.  Induction of peroxisomal β-oxidation in the rat liver in vivo and in vitro by tetrazole-substituted acetophenones: Structure-activity relationships , 1989 .

[67]  D. Johnston,et al.  Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[68]  K. Kripalani,et al.  Biotransformation of irbesartan in man. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[69]  Alan R. Katritzky,et al.  Comprehensive Heterocyclic Chemistry IV , 1996 .

[70]  B. Narayanan,et al.  An Efficient Synthesis of an Angiotensin II Antagonist (A-81988) , 1993 .

[71]  T. B. Lee,et al.  Antagonists of slow reacting substance of anaphylaxis. Synthesis of a series of chromone-2-carboxylic acids. , 1977, Journal of medicinal chemistry.

[72]  Sabine Hadida,et al.  tris(2-perfluorohexylethyl)tin azide: A new reagent for preparation of 5-substituted tetrazoles from nitriles with purification by fluorous/organic liquid-liquid extraction , 1999 .

[73]  F. Itoh,et al.  Non-glutamate type pyrrolo[2,3-d]pyrimidine antifolates. I: Synthesis and biological properties of pyrrolo[2,3-d]pyrimidine antifolates containing tetrazole congener of glutamic acid. , 1995, Chemical & pharmaceutical bulletin.

[74]  Alterman,et al.  Fast microwave-assisted preparation of aryl and vinyl nitriles and the corresponding tetrazoles from organo-halides , 2000, The Journal of organic chemistry.

[75]  F. A. Amer,et al.  A novel approach for the synthesis of 5-substituted tetrazole derivatives from primary amides in mild one-step method , 1997 .

[76]  Yoshinori Yamamoto,et al.  Regiospecific synthesis of 2-allylated-5-substituted tetrazoles via palladium-catalyzed reaction of nitriles, trimethylsilyl azide, and allyl acetates , 2000 .

[77]  Y. Sanno,et al.  Studies on antianaphylactic agents. 6. Synthesis of some metabolites of 6-ethyl-3-(1H-tetrazol-5-yl)chromone and their analogues. , 1979, Journal of medicinal chemistry.

[78]  G R Marshall,et al.  Conformational mimicry. II. An obligatory cis amide bond in a small linear peptide. , 2009, International journal of peptide and protein research.

[79]  B. Jursic,et al.  Preparation of 5-Alkylthio and 5-Arylthiotetrazoles from Thiocyanates Using Phase Transfer Catalysis , 1998 .

[80]  J. Mestan,et al.  New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development. , 1998, Journal of medicinal chemistry.

[81]  S. Pong,et al.  A nonpeptidyl growth hormone secretagogue. , 1993, Science.

[82]  Steven Whitebread,et al.  Valsartan, a potent, orally active angiotensin II antagonist developed from the structurally new amino acid series , 1994 .

[83]  G. Mihm,et al.  6-Substituted benzimidazoles as new nonpeptide angiotensin II receptor antagonists: synthesis, biological activity, and structure-activity relationships. , 1993, Journal of medicinal chemistry.

[84]  Christopher A. Lipinski,et al.  Chapter 27. Bioisosterism in Drug Design , 1986 .

[85]  A. Liwo,et al.  Solution conformational study of Scyliorhinin I analogues with conformational constraints by two-dimensional NMR and theoretical conformational analysis. , 2000, The journal of peptide research : official journal of the American Peptide Society.

[86]  H. Terada,et al.  Structural requirements of leukotriene antagonists , 1995 .

[87]  M. Lebl,et al.  Analogs of oxytocin containing a pseudopeptide Leu-Gly bond of cis and trans configuration. , 2009, International journal of peptide and protein research.

[88]  L. Prézeau,et al.  Synthesis and biological evaluation of 2-(3'-(1H-tetrazol-5-yl) bicyclo[1.1.1]pent-1-yl)glycine (S-TBPG), a novel mGlu1 receptor antagonist. , 2001, Bioorganic & medicinal chemistry.

[89]  T. Lee,et al.  The development of a novel series of (quinolin-2-ylmethoxy)phenyl-containing compounds as high-affinity leukotriene receptor antagonists. 3. Structural variation of the acidic side chain to give antagonists of enhanced potency. , 1990, Journal of medicinal chemistry.

[90]  P. Bernstein,et al.  Improved Conditions for the Formation of Tetrazoles , 1987 .

[91]  L. García-Marcos,et al.  Antileukotrienes in asthma: present situation , 2001, Expert opinion on pharmacotherapy.

[92]  H. J. Hess,et al.  Synthesis and biological activity of carboxyl-terminus modified prostaglandin analogues. , 1979, Journal of medicinal chemistry.

[93]  J. Falgueyret,et al.  Substituted thiopyrano[2,3,4-c,d]indoles as potent, selective, and orally active inhibitors of 5-lipoxygenase. Synthesis and biological evaluation of L-691,816. , 1993, Journal of medicinal chemistry.

[94]  J. Shire.  Growth Hormone and Premature Ageing , 1973, Nature.

[95]  D. Noonan,et al.  Common Structural Requirements for Peroxisome Proliferation by Tetrazole and Carboxylic Acid‐Containing Compounds , 1996, Annals of the New York Academy of Sciences.

[96]  Z. Grzonka,et al.  Synthesis of γ-tetrazole analogues of l-glutamic acid and its derivatives , 1977 .

[97]  T. B. Lee,et al.  Further studies on the SRS-A antagonist FPL 55712. , 1977, Monographs in allergy.

[98]  J. Cannon,et al.  Interaction of LY171883 and other peroxisome proliferators with fatty-acid-binding protein isolated from rat liver. , 1991, Biochemical Journal.

[99]  Garland R. Marshall,et al.  Conformational mimicry. 3. Synthesis and incorporation of 1,5-disubstituted tetrazole dipeptide analogs into peptides with preservation of chiral integrity: bradykinin , 1992 .

[100]  A. Jackman,et al.  Carboxylic acid bioisosteres of γ-linked dipeptide analogues of the folate-based thymidylate synthase (TS) inhibitor, 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583) , 1996 .

[101]  H. Timmerman,et al.  THE ROLE OF ARGININE IN THE BINDING OF LTD4 ANTAGONISTS TO cysLT1 RECEPTORS OF GUINEA PIG LUNG , 1997 .

[102]  A. Kraft,et al.  Noncovalent interactions between tetrazole and an N,N'-diethyl-substituted benzamidine. , 2001, The Journal of organic chemistry.

[103]  R. M. Herbst,et al.  Synthesis of Iminotetrazoline Derivatives as Trichomonacidal and Fungicidal Agents1, 2 , 1957 .

[104]  M. Fisher,et al.  Acyclic structural variants of growth hormone secretagogue L-692,429. , 1999, Bioorganic & medicinal chemistry letters.

[105]  P. Ornstein,et al.  Heteroatom-substitution as a strategy for increasing the potency of competitive NMDA antagonists. , 1998, Bioorganic & medicinal chemistry letters.

[106]  J. Taylor,et al.  Efficacy and specificity of L-692,429, a novel nonpeptidyl growth hormone secretagogue, in beagles. , 1994, Endocrinology.

[107]  R. N. Butler.  Recent Advances in Tetrazole Chemistry , 1977 .

[108]  Y. Satoh,et al.  Synthesis of tetrazole analogs of α-amino acids by alkylation of a Schiff base of α-aminomethyltetrazole , 1998 .

[109]  R. Miller,et al.  Absorption and glucuronidation of the angiotensin II receptor antagonist losartan by the rat intestine. , 1995, The Journal of pharmacology and experimental therapeutics.

[110]  T. Goodson,et al.  Leukotriene receptor antagonists. 1. Synthesis and structure-activity relationships of alkoxyacetophenone derivatives. , 1987, Journal of medicinal chemistry.

[111]  Roy G. Smith,et al.  The design and synthesis of orally active short duration spiroindane growth hormone secretagogues , 1997 .

[112]  J. McMurray,et al.  Convenient preparation of 4-(tetrazol-5-yl)-phenylalanine for use in Fmoc-based solid-phase peptide synthesis , 2000 .

[113]  S. Wittenberger,et al.  Dialkyltin oxide mediated addition of trimethylsilyl azide to nitriles. A novel preparation of 5-substituted tetrazols , 1993 .

[114]  H. Terada,et al.  Quantitative structure-activity relationships of benzamide derivatives for anti-leukotriene activities. , 1992, Journal of medicinal chemistry.

[115]  B. C. Bookser.  2-Benzyloxymethyl-5-(tributylstannyl)tetrazole. A reagent for the preparation of 5-aryl- and 5-heteroaryl-1H-tetrazoles via the Stille reaction† , 2000 .

[116]  M. Kuhar,et al.  Synthesis, Ligand Binding, and Quantitative Structure−Activity Relationship Study of 3β-(4‘-Substituted phenyl)-2β-heterocyclic Tropanes: Evidence for an Electrostatic Interaction at the 2β-Position , 1996 .

[117]  J. Reindel,et al.  Inhibitors of acyl-CoA:cholesterol O-acyltransferase. synthesis and pharmacological activity of (+/-)-2-dodecyl-alpha-phenyl-N-(2,4,6-trimethoxyphenyl)-2H-tetrazole-5- acetamide and structurally related tetrazole amide derivatives. , 1996, Journal of Medicinal Chemistry.

[118]  Y. Satoh,et al.  Application of 5-lithiotetrazoles in organic synthesis , 1995 .

[119]  P. Kadaba.  Role of Protic and Dipolar Aprotic Solvents in Heterocyclic Syntheses via 1,3-Dipolar Cycloaddition Reactions , 1973 .

[120]  T. Maduskuie,et al.  Hydroxyacetophenone-derived antagonists of the peptidoleukotrienes. , 1989, Journal of Medicinal Chemistry.

[121]  R. DeVita,et al.  BENZOLACTAM GROWTH HORMONE SECRETAGOGUES , 1996 .

[122]  K. Sharpless,et al.  Preparation of 5-substituted 1H-tetrazoles from nitriles in water. , 2001, The Journal of organic chemistry.

[123]  W. S. Marshall,et al.  A Brief Review of Preclinical and Clinical Studies with LY171883 and Some Comments on Newer Cysteinyl Leukotriene Receptor Antagonists , 1988, Annals of the New York Academy of Sciences.

[124]  R. Miller,et al.  Synthesis and identification of a novel tetrazole metabolite of the angiotensin II receptor antagonist DuP 753. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[125]  Garland R. Marshall,et al.  Conformational mimicry. 1. 1,5-Disubstituted tetrazole ring as a surrogate for the cis amide bond , 1988 .

[126]  M. Fisher,et al.  A novel 3-substituted benzazepinone growth hormone secretagogue (L-692,429). , 1994, Journal of medicinal chemistry.

[127]  T. Hansen,et al.  INVESTIGATION OF BIOISOSTERS OF THE GROWTH HORMONE SECRETAGOGUE L-692,429. , 1997 .

[128]  D K Herron,et al.  Development of a series of phenyltetrazole leukotriene D4 (LTD4) receptor antagonists. , 1992, Journal of medicinal chemistry.

[129]  D. Hoyer,et al.  Potent and selective non-peptidic inhibitors of endothelin-converting enzyme-1 with sustained duration of action. , 2000, Journal of medicinal chemistry.

[130]  R. Orita,et al.  Novel Synthesis of 5-Substituted Tetrazoles from Nitriles , 1998 .

[131]  J. Simiand,et al.  Disposition of irbesartan, an angiotensin II AT1-receptor antagonist, in mice, rats, rabbits, and macaques. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[132]  R. Miller,et al.  N-glucuronidation reactions. II. Relative N-glucuronidation reactivity of methylbiphenyl tetrazole, methylbiphenyl triazole, and methylbiphenyl imidazole in rat, monkey, and human hepatic microsomes. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[133]  N. Sadlej-Sosnowska.  Application of natural bond orbital analysis to delocalization and aromaticity in C-substituted tetrazoles. , 2001, The Journal of organic chemistry.

[134]  B. E. Evans,et al.  Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. , 1988, Journal of Medicinal Chemistry.

[135]  S. Wittenberger.  RECENT DEVELOPMENTS IN TETRAZOLE CHEMISTRY. A REVIEW , 1994 .